VKH
LRMR icon

Virtu KCG Holdings’s Larimar Therapeutics LRMR Stock Holding History

Virtu KCG Holdings’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$97K Buy
2,308
+1,194
+107% +$61.1K ﹤0.01% 2424
2017
Q1 		$62K Sell
1,114
-265
-19% -$13.2K ﹤0.01% 2795
2016
Q4 		$53K Sell
1,379
-3,710
-73% -$150K ﹤0.01% 3077
2016
Q3 		$202K Buy
+5,089
New +$231K ﹤0.01% 2360

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Virtu KCG Holdings's LRMR Position: Q2 2017 in Review

Virtu KCG Holdings increased its Larimar Therapeutics (LRMR) stake by 107% in Q2 2017, buying an estimated $61.1K and bringing the position to 2,308 shares worth $97K. The position accounts for ﹤0.01% of the portfolio, ranked #2424.

Virtu KCG Holdings first reported a position in LRMR in Q3 2016 and has held it in 4 quarters since. The position peaked at $202K in Q3 2016. 69 funds tracked by Wall St. Rank hold LRMR as of Q2 2017.

  • Virtu KCG Holdings held 2,308 shares of Larimar Therapeutics worth $97K as of Q2 2017.
  • Virtu KCG Holdings bought 1,194 Larimar Therapeutics shares in Q2 2017, an estimated $61.1K.
  • Larimar Therapeutics made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2424 holding.
  • Virtu KCG Holdings first reported a position in Larimar Therapeutics in Q3 2016 and has held it in 4 quarters since.
  • Virtu KCG Holdings's Larimar Therapeutics position peaked at $202K in Q3 2016.
  • 69 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.